← Back to Search

Vaccine

mRNA-1345: Exposed for Respiratory Syncytial Virus

N/A
Waitlist Available
Research Sponsored by ModernaTX, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

The main goal of this observational study is to evaluate the real-world effectiveness of the Moderna mRNA-1345 vaccine for protection against RSV lower respiratory tract disease (RSV-LRTD) and to study additional health and economic outcomes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cardiovascular system
Secondary outcome measures
Death Rate Within 30 Days, 31-365 Days, and up to 3 Years After mRNA-1345 Exposure
Incidence Rate of Discharge to Long-term or Short-term Institutional Care Following Hospitalization for All-cause, Cardiopulmonary/Cardiovascular, Pneumonia/Influenza, or RSV
Length of Stay of Hospitalizations Related to All-Causes, Cardiopulmonary/Cardiovascular, Pneumonia/Influenza, or RSV
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: mRNA-1345: ExposedExperimental Treatment1 Intervention
Eligible US participants from the mRNA-1345-P301 (P301) study who received the mRNA-1345 vaccine.
Group II: Placebo/Control: ReferentExperimental Treatment1 Intervention
Eligible US participants from the P301 study who received placebo and eligible US-based, matched, unvaccinated RWD participants.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

ModernaTX, Inc.Lead Sponsor
108 Previous Clinical Trials
61,368,307 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
2022. "Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05572658.
All > Honolulu
~1049 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top